Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells.
about
Role of nuclear receptors in breast cancer stem cellsCancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer TreatmentNanomedicine-Mediated Therapies to Target Breast Cancer Stem CellsEfficient co-delivery of immiscible hydrophilic/hydrophobic chemotherapeutics by lipid emulsions for improved treatment of cancer.Recent advances of cocktail chemotherapy by combination drug delivery systems.HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24.The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies.Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy.Modifying the tumor microenvironment using nanoparticle therapeuticsOrganic nanoparticle systems for spatiotemporal control of multimodal chemotherapy.Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer.HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells.Cancer Nanomedicines Stabilized by π-π Stacking between Heterodimeric Prodrugs Enable Exceptionally High Drug Loading Capacity and Safer Delivery of Drug Combinations.All-trans-retinoic acid ameliorates doxorubicin-induced cardiotoxicity: in vivo potential involvement of oxidative stress, inflammation, and apoptosis via caspase-3 and p53 down-expression.A micellar cisplatin prodrug simultaneously eliminates both cancer cells and cancer stem cells in lung cancer.All-trans retinoic acid inhibits the proliferation of SGC7901 cells by regulating caveolin-1 localization via the ERK/MAPK signaling pathway.A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation.PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan.Ratiometric delivery of two therapeutic candidates with inherently dissimilar physicochemical property through pH-sensitive core-shell nanoparticles targeting the heterogeneous tumor cells of glioma.pH and redox dual-responsive copolymer micelles with surface charge reversal for co-delivery of all--retinoic acid and paclitaxel for cancer combination chemotherapy
P2860
Q26750359-B001C799-2863-45AA-B9AF-A57D7EC428DAQ27024816-52A7C667-EC72-4EF7-8282-894231FA59B5Q28066297-CD6B3FC7-7CBE-466D-8DD3-F95A2312F41EQ33563252-4BDD6798-2717-4DA3-A97C-A08A8400468CQ37206908-E35C6BE0-1905-4821-82AB-7F0422677B89Q37354916-95C9BE9B-E471-441F-8850-5EA8BC57DF52Q38645695-704A6D26-45C4-493F-85EE-CCBB24A7A5F7Q38664820-2B61EE9B-71F7-49B1-A3D8-2722DDA74233Q38796320-85A4E1EB-A1AA-478B-A51A-F924BC65FF71Q38836010-AE7903D7-8ABC-4210-937C-4F78EBDF83CBQ41514180-55771466-BBE2-41EC-AE9B-3EBDB327E874Q41854729-BD64848C-2523-4431-8F01-A47608CDF309Q43095122-17FDDA41-9D67-4B08-8E49-AA1418758C50Q46594579-7A10FB2F-13AB-489E-ABA5-F43F2ED1050BQ48329456-A8AE4B97-DFE2-44A8-8F13-5EA63DAB844EQ49612712-60917B51-6D94-4943-9C2B-3955D20A585BQ49857972-5D67B51B-307D-44C9-8163-E000F1C58DAAQ50587758-F545FC7E-2899-4C95-A282-466FD7F1836BQ55456898-ECDF0BD8-1BF1-46D8-840C-15169CD38620Q58555827-33DD4B2C-0803-4260-977F-75A898FF35AE
P2860
Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Co-delivery of all-trans-retin ...... hibition of cancer stem cells.
@en
type
label
Co-delivery of all-trans-retin ...... hibition of cancer stem cells.
@en
prefLabel
Co-delivery of all-trans-retin ...... hibition of cancer stem cells.
@en
P2093
P50
P1433
P1476
Co-delivery of all-trans-retin ...... hibition of cancer stem cells.
@en
P2093
Shi-Yong Li
Ya-Ping Li
Yan-Hua Zhu
Zhi-Ting Cao
P304
P356
10.1016/J.BIOMATERIALS.2014.10.018
P577
2014-10-23T00:00:00Z